Paediatric GLP-1 drugs in India face closer scrutiny after WHO prioritised lifestyle interventions and called for stronger evidence before wider use in children.
Neuberg and NM Medical’s merger strengthens Maharashtra’s preventive healthcare network, combining advanced diagnostics, imaging and wellness services with a Rs 500 crore revenue target.
Complex injectables in Indian pharma are gaining importance as companies invest in specialised R&D, complex formulations, and higher-value drug development.
India’s biopharma leap is gaining momentum as peptides and ADCs drive investment, advanced therapeutics, precision diagnostics and manufacturing growth.
Glenmark adapalene 0.1 percent launch in the US highlights an established acne therapy and its relevance to India's evolving dermatology treatment landscape.
Zydus advances its specialty ambitions with the first generic Adempas launch in the U.S., expanding access to lower-cost pulmonary hypertension treatment.
Epcoritamab DLBCL treatment gains momentum as AbbVie and Genmab report a 51 percent reduction in progression or death risk.
Serum Institute’s WHO nod for Cervavac strengthens India’s cancer-free vision by expanding access to an indigenous HPV vaccine.
Sterile drug licensing in India could shift to CDSCO as the Centre examines central oversight following 240 NSQ injection samples in 2025-26.
Lupin Limited has launched Formoflo-G MDI, a fixed-dose triple-combination metered-dose inhaler for COPD treatment in India. The launch, announced on October 6, 2026, expands the company’s respiratory care portfolio and adds another...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
